Scroll

nelfinavir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
HIV protease inhibitors	1893	159989-64-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nelfinavir viracept nelfinavir mesylate nelfinavir mesilate	A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. There was some evidence of in vitro activity against SARS-CoV-2, but no clinical trial data was found to support use in the treatment of COVID-19. Molecular weight: 567.79 Formula: C32H45N3O4S CLOGP: 5.84 LIPINSKI: 2 HAC: 7 HDO: 4 TPSA: 101.90 ALOGS: -5.47 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nelfinavir
viracept
nelfinavir mesylate
nelfinavir mesilate

A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. There was some evidence of in vitro activity against SARS-CoV-2, but no clinical trial data was found to support use in the treatment of COVID-19.

Molecular weight: 567.79
Formula: C32H45N3O4S
CLOGP: 5.84
LIPINSKI: 2
HAC: 7
HDO: 4
TPSA: 101.90
ALOGS: -5.47
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2.25	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	62.90 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
March 14, 1997	FDA	AGOURON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	504.45	48.50	182	1658	155365	63331817
Pregnancy	208.43	48.50	66	1774	36770	63450412
Stillbirth	200.47	48.50	45	1795	6705	63480477
Viral mutation identified	186.49	48.50	34	1806	1776	63485406
Caesarean section	172.82	48.50	48	1792	16984	63470198
Abortion spontaneous	124.75	48.50	48	1792	47147	63440035
Drug resistance	120.88	48.50	39	1801	22894	63464288
Premature baby	120.57	48.50	38	1802	20697	63466485
Foetal exposure during pregnancy	119.59	48.50	42	1798	31920	63455262
Maternal drugs affecting foetus	102.90	48.50	25	1815	5217	63481965
Hypertriglyceridaemia	93.58	48.50	24	1816	6235	63480947
Blood lactic acid increased	85.87	48.50	23	1817	7063	63480119
Pathogen resistance	78.63	48.50	21	1819	6377	63480805
Lipodystrophy acquired	73.25	48.50	15	1825	1437	63485745
Premature labour	64.73	48.50	21	1819	12483	63474699
Normal newborn	64.26	48.50	19	1821	8322	63478860
Virologic failure	63.93	48.50	14	1826	1848	63485334
Live birth	63.81	48.50	25	1815	25605	63461577
Atrial septal defect	63.19	48.50	18	1822	6920	63480262
Abortion induced	60.41	48.50	19	1821	10223	63476959
Multiple-drug resistance	58.95	48.50	16	1824	5154	63482028
Patent ductus arteriosus	57.22	48.50	15	1825	4235	63482947
Foetal death	55.04	48.50	18	1822	10962	63476220
Trisomy 21	51.04	48.50	9	1831	386	63486796

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Lipodystrophy acquired	500.42	35.44	104	3211	3240	34950376
Mitochondrial toxicity	421.50	35.44	87	3228	2612	34951004
Exposure during pregnancy	379.44	35.44	100	3215	8834	34944782
Progressive external ophthalmoplegia	374.16	35.44	71	3244	1364	34952252
Eyelid ptosis	365.95	35.44	89	3226	5677	34947939
Diplopia	251.48	35.44	84	3231	16759	34936857
Foetal exposure during pregnancy	233.74	35.44	99	3216	38002	34915614
Viral mutation identified	120.06	35.44	32	3283	2922	34950694
Virologic failure	119.46	35.44	33	3282	3447	34950169
Pathogen resistance	116.76	35.44	41	3274	9441	34944175
Ophthalmoplegia	109.41	35.44	27	3288	1813	34951803
Premature baby	103.68	35.44	46	3269	19587	34934029
Hydrocele	77.22	35.44	21	3294	2066	34951550
Maternal drugs affecting foetus	76.21	35.44	24	3291	3941	34949675
Hypertriglyceridaemia	72.42	35.44	28	3287	8420	34945196
Cryptorchism	63.83	35.44	18	3297	2023	34951593
Caesarean section	62.79	35.44	18	3297	2146	34951470
Drug resistance	60.57	35.44	35	3280	25892	34927724
Blood lactic acid increased	56.60	35.44	22	3293	6706	34946910
Lipoatrophy	54.21	35.44	12	3303	499	34953117
Optic nerve neoplasm	54.09	35.44	8	3307	28	34953588
Neonatal disorder	53.49	35.44	13	3302	817	34952799
Multiple-drug resistance	50.78	35.44	19	3296	5220	34948396
Pregnancy	49.14	35.44	10	3305	276	34953340
Anaemia neonatal	48.12	35.44	10	3305	307	34953309
Cardiac murmur	46.65	35.44	20	3295	7817	34945799
Hyperlactacidaemia	44.72	35.44	15	3300	3001	34950615
Dyslipidaemia	44.21	35.44	19	3296	7469	34946147
Hypospadias	43.84	35.44	15	3300	3186	34950430
Astrocytoma, low grade	43.82	35.44	7	3308	45	34953571
Congenital anomaly	42.26	35.44	12	3303	1381	34952235

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Lipodystrophy acquired	597.91	35.18	111	3397	4214	79736666
Mitochondrial toxicity	501.71	35.18	91	3417	3023	79737857
Progressive external ophthalmoplegia	435.14	35.18	72	3436	1373	79739507
Eyelid ptosis	371.12	35.18	88	3420	10956	79729924
Viral mutation identified	281.03	35.18	58	3450	3800	79737080
Diplopia	258.15	35.18	84	3424	33382	79707498
Exposure during pregnancy	245.68	35.18	109	3399	101023	79639857
Stillbirth	172.47	35.18	39	3469	3916	79736964
Virologic failure	170.22	35.18	39	3469	4152	79736728
Drug resistance	168.53	35.18	65	3443	42148	79698732
Pregnancy	165.59	35.18	57	3451	26794	79714086
Pathogen resistance	165.23	35.18	49	3459	14293	79726587
Multiple-drug resistance	123.18	35.18	35	3473	8773	79732107
Caesarean section	115.17	35.18	36	3472	12499	79728381
Ophthalmoplegia	112.36	35.18	26	3482	2886	79737994
Abortion spontaneous	102.09	35.18	41	3467	29466	79711414
Premature baby	76.02	35.18	20	3488	3760	79737120
Optic nerve neoplasm	61.17	35.18	8	3500	24	79740856
Lipoatrophy	59.83	35.18	12	3496	677	79740203
Normal newborn	59.49	35.18	19	3489	7053	79733827
Dyslipidaemia	57.58	35.18	21	3487	11612	79729268
Foetal exposure during pregnancy	54.71	35.18	17	3491	5773	79735107
Maternal drugs affecting foetus	44.10	35.18	11	3497	1672	79739208
Abortion induced	43.40	35.18	15	3493	7094	79733786
Osteonecrosis	43.35	35.18	23	3485	31072	79709808
HIV-associated neurocognitive disorder	42.00	35.18	8	3500	344	79740536
Live birth	41.48	35.18	19	3489	18725	79722155
Astrocytoma, low grade	40.59	35.18	6	3502	52	79740828
Blood HIV RNA increased	38.44	35.18	10	3498	1798	79739082
Hypertriglyceridaemia	38.22	35.18	16	3492	12724	79728156

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J05AE04	ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Protease inhibitors
FDA MoA	N0000000246	HIV Protease Inhibitors
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35660	HIV protease inhibitors
FDA EPC	N0000175889	Protease Inhibitor
FDA MoA	N0000190114	Cytochrome P450 3A Inhibitors
MeSH PA	D019380	Anti-HIV Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D044966	Anti-Retroviral Agents
MeSH PA	D000998	Antiviral Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D017320	HIV Protease Inhibitors
MeSH PA	D011480	Protease Inhibitors
MeSH PA	D000084762	Viral Protease Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Human immunodeficiency virus infection	indication	86406008	DOID:526
Depressive disorder	contraindication	35489007
Diarrhea	contraindication	62315008
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Hemophilia	contraindication	90935002
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.66	acidic
pKa2	11.97	acidic
pKa3	6.63	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.19	DRUG MATRIX
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	5.70	DRUG MATRIX
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.70	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.06	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	4.21	DRUG MATRIX
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	4.59	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	4.91	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.08	DRUG MATRIX
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	4.84	DRUG MATRIX
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	4.90	CHEMBL
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	4.63	DRUG MATRIX
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	4.26	DRUG MATRIX
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		IC50	4.10	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.10	DRUG MATRIX
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	4.68	DRUG MATRIX
Mitogen-activated protein kinase 3	Kinase	P27361	MK03_HUMAN		IC50	4.65	DRUG MATRIX
Mitogen-activated protein kinase 14	Kinase	Q16539	MK14_HUMAN		IC50	4.74	DRUG MATRIX
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.01	DRUG MATRIX
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	5.23	DRUG MATRIX
Pol polyprotein	Enzyme		Q72874_9HIV1	INHIBITOR	Ki	11	CHEMBL	CHEMBL
Gag-Pol polyprotein	Polyprotein		POL_HV1BR				WOMBAT-PK
Androgen receptor	Transcription factor		ANDR_RAT		Ki	4.62	DRUG MATRIX
Arachidonate 15-lipoxygenase	Enzyme		LOX15_RABIT		IC50	4.86	DRUG MATRIX
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	5.24	DRUG MATRIX
Protease	Enzyme		Q9YQ12_9HIV1		Ki	10.15	CHEMBL
Protease	Unclassified		O90781_9PLVG		Ki	8.49	CHEMBL
Protease	Unclassified		Q9YQ30_9PLVG		Ki	8.68	CHEMBL

External reference:

ID	Source
4024050	VUID
N0000022055	NUI
D00899	KEGG_DRUG
159989-65-8	SECONDARY_CAS_RN
4021010	VANDF
4024050	VANDF
C0525005	UMLSCUI
CHEBI:7496	CHEBI
1UN	PDB_CHEM_ID
CHEMBL584	ChEMBL_ID
CHEMBL1205	ChEMBL_ID
D019888	MESH_DESCRIPTOR_UI
DB00220	DRUGBANK_ID
11090	IUPHAR_LIGAND_ID
7494	INN_ID
HO3OGH5D7I	UNII
64143	PUBCHEM_CID
134526	RXNORM
5162	MMSL
9815	MMSL
d04118	MMSL
006408	NDDF
006409	NDDF
108706004	SNOMEDCT_US
108707008	SNOMEDCT_US
373445001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VIRACEPT	HUMAN PRESCRIPTION DRUG LABEL	1	52959-289	TABLET, FILM COATED	250 mg	ORAL	NDA	26 sections
Viracept	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0809	TABLET, FILM COATED	625 mg	ORAL	NDA	25 sections
VIRACEPT	HUMAN PRESCRIPTION DRUG LABEL	1	63010-010	TABLET, FILM COATED	250 mg	ORAL	NDA	29 sections
VIRACEPT	HUMAN PRESCRIPTION DRUG LABEL	1	63010-010	TABLET, FILM COATED	250 mg	ORAL	NDA	29 sections
VIRACEPT	HUMAN PRESCRIPTION DRUG LABEL	1	63010-027	TABLET, FILM COATED	625 mg	ORAL	NDA	29 sections
VIRACEPT	HUMAN PRESCRIPTION DRUG LABEL	1	63010-027	TABLET, FILM COATED	625 mg	ORAL	NDA	29 sections